For this reason, we evaluated the effect exerted by SFN and FB, administered individually or in combination (Figure 5), on the NLRP3 inflammasome components, as well as on the products of their activation (cleaved caspase-1 and IL-1β) in WM266-4 melanoma cells. The gene discussed is NLRP3; the disease is melanoma.